Kirill Osipov comments on regulation of dependent inventions in Russia

Kirill Osipov, the Head of Legal Department of ARS-Patent, commented on regulation of dependent inventions in Russia for the newspaper “Pharmvestnik” in the light of the Moscow Arbitration Court’s Decision of June 1, 2018, according to which, a first compulsory license may be granted in Russia to a medicament comprising INN Lenalidomide.

More details are available at Pharmvestnik’s website.

Pharmvestnik is the leading specialized weekly newspaper covering the Russian pharmaceutical and related industries with a circulation of 16 200 copies. The newspaper has been issued since 1994.

Make an enquiry

Latest News

IAM Patent 1000 2021: ARS-Patent is named the Highly recommended Russian IP firm

2021-07-06

Intellectual Asset Management (IAM) announced the results of the annual ranking IAM Patent 1000 which identifies the world's leading patent profession...

Read more
ARS-Patent recognised in the MIP IP STARS 2021 ranking

2021-07-02

ARS-Patent’s practices have been distinguished in the 2021 edition of the Managing Intellectual Property ranking IP STARS. The results of our wor...

Read more

View all our News

MEET WITH US

Meet with us at 2019 AIPLA Annual Meeting

2019-10-18

Kirill Osipov, the Head of Legal Department at ARS-Patent, will be attending 2019 AIPLA Annual Meeting on October 24-26 in National Harbor, MD, USA. ...

Read more
Meet ARS-Patent at 4th China Pharma Intellectual Property Summit 2019

2019-10-18

Mikhail Khmara, Managing Partner of ARS-Patent and the Head of Patent Department will attend 4th China Pharma IP Summit 2019 (CPIPS 2019) on October 2...

Read more

See all Events

Back top